Shares of Spanish biotech company Oryzon Genomics plummeted more than 23 percent after Swiss drug giant Roche ended a three-year-old developmental deal for the company’s leukemia and cancer treatments.
French drugmaker Sanofi boosted its early-stage pipeline in immunology by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).
People who typically work much more than 35 to 40 hours a week may be at heightened risk of developing atrial fibrillation, an irregular rapid heartbeat that can lead to strokes, heart failure and chronic fatigue, a recent study suggests.
A psychiatric hospital in Belgium is home to one of the world’s largest collections of human brains, which researchers say could hold the key to developing new treatments for diseases such as psychosis, schizophrenia and severe depression.
The European Medicines Agency (EMA), eager to accelerate access to promising new drugs, may be getting too cozy with the pharmaceutical companies it regulates.
Siemens Healthineers broke ground on a $300 million expansion at its Massachusetts-based laboratory diagnostics, manufacturing and research and development facility.
Novartis CEO Joe Jiminez spoke with investors and analysts regarding the company’s half-year financials.
As their seven-year effort to repeal and replace Obamacare derailed in the U.S. Senate, Republicans faced the prospect of doing the once unthinkable: working with Democrats to make fixes to former President Barack Obama’s 2010 healthcare law.
The FDA approved Gilead Sciences’ Vosevi, an oral medicine for the re-treatment of chronic HCV.
Vertex Pharmaceuticals announced positive efficacy data from its Phase I and Phase II studies of three different triple combination regimens for cystic fibrosis patients,